Last reviewed · How we verify
NCT05671432
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
Phase 2 trial testing CM326 in Moderate-to-severe Atopic Dermatitis in 240 participants. Status unknown.
30 December 2023
Quick facts
| Lead sponsor | Keymed Biosciences Co.Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 240 |
| Start date | 27 December 2022 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CM326 — full drug profile →
- Placebo
Conditions studied
- Moderate-to-severe Atopic Dermatitis — all drugs for Moderate-to-severe Atopic Dermatitis →
Sponsor
Keymed Biosciences Co.Ltd — full company profile →
Who can join
Adults 18 to 75, any sex, with Moderate-to-severe Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial.
Xian M, Lan F, Yan B, Shen S, et al · · 2025 · cited 3× · PMID 41022848 · DOI 10.1038/s41467-025-63682-x
Verify or expand the search:
- PubMed search for NCT05671432
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CM326
Trials testing the same drug.
- NCT07372287 — A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma · Phase 3 · not yet recruiting
- NCT06372678 — Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis · Phase 2 · not yet recruiting
- NCT05715333 — Study of CM326 Injection in Healthy Subjects · Phase 1 · completed
- NCT05671445 — The Study of CM326 in Adult Subjects With Atopic Dermatitis · Phase 2 · unknown
- NCT05324137 — A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps · Phase 1, PHASE2 · completed
Other recruiting trials for Moderate-to-severe Atopic Dermatitis
Currently open trials in the same condition.
- NCT06934252 — Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients · Phase 1 · recruiting
- NCT03057860 — TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis · recruiting
Other Keymed Biosciences Co.Ltd trials
Trials by the same sponsor.
- NCT07519577 — A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2） · Phase 2 · not yet recruiting
- NCT07166211 — Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) · Phase 2 · recruiting
- NCT07175493 — A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia · Phase 1, PHASE2 · recruiting
- NCT07011524 — Study of CM512 Injection in Subjects With Moderate-to-severe Asthma · Phase 2 · recruiting
- NCT07039578 — Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05671432 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Keymed Biosciences Co.Ltd
- Last refreshed: 4 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05671432.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing